173 related articles for article (PubMed ID: 34871523)
1. Research progress on treatment of extramedullary multiple myeloma.
Chen Y; Tao S; Zheng X; Shi Y; Zhang L; Chen K; He Z; Wang C; Yu L
Hematology; 2021 Dec; 26(1):985-994. PubMed ID: 34871523
[No Abstract] [Full Text] [Related]
2. Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature.
Qian Y; Qian Z; Zhao X; Pan W; Wei X; Meng H; Yang L; Xiao H
Front Med (Lausanne); 2021; 8():649824. PubMed ID: 34026784
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
4. How I treat extramedullary myeloma.
Touzeau C; Moreau P
Blood; 2016 Feb; 127(8):971-6. PubMed ID: 26679866
[TBL] [Abstract][Full Text] [Related]
5. Extramedullary multiple myeloma.
Bhutani M; Foureau DM; Atrash S; Voorhees PM; Usmani SZ
Leukemia; 2020 Jan; 34(1):1-20. PubMed ID: 31776467
[TBL] [Abstract][Full Text] [Related]
6. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Tirumani SH; Sakellis C; Jacene H; Shinagare AB; Munshi NC; Ramaiya NH; Van den Abbeele AD
Clin Nucl Med; 2016 Jan; 41(1):e7-13. PubMed ID: 26252323
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T cell therapies for multiple myeloma.
Wu C; Zhang L; Brockman QR; Zhan F; Chen L
J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
[TBL] [Abstract][Full Text] [Related]
8. Current developments in immunotherapy in the treatment of multiple myeloma.
Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M
Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124
[TBL] [Abstract][Full Text] [Related]
9. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
10. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on the Treatment of Multiple Myeloma.
Rafae A; van Rhee F; Al Hadidi S
Oncologist; 2024 Mar; 29(3):200-212. PubMed ID: 37995307
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Koehne G; Giralt S
Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
[TBL] [Abstract][Full Text] [Related]
13. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
Zanwar S; Ho M; Lin Y; Kapoor P; Binder M; Buadi FK; Dispenzieri A; Dingli D; Fonder A; Gertz MA; Gonsalves W; Hayman SR; Hwa Y; Hobbs M; Kourelis T; Lacy MQ; Leung N; Muchtar E; Warsame R; Jevremovic D; Kyle RA; Rajkumar SV; Kumar S
Am J Hematol; 2023 Oct; 98(10):1540-1549. PubMed ID: 37421603
[TBL] [Abstract][Full Text] [Related]
14. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
15. CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
Smith E; Devlin SM; Kosuri S; Orlando E; Landau H; Lesokhin AM; Chung DJ; Hassoun H; Lendvai N; Landgren O; Giralt S; Chari A; Jagannath S; Koehne G
Biol Blood Marrow Transplant; 2016 Feb; 22(2):258-267. PubMed ID: 26325439
[TBL] [Abstract][Full Text] [Related]
16. Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.
Farre L; Sanz G; Ruiz-Xivillé N; Castro de Moura M; Martin-Tejera JF; Gonçalves-Ribeiro S; Martinez-Iniesta M; Calaf M; Luis Mosquera J; Martín-Subero JI; Granada I; Esteller M; Domingo-Domenech E; Climent F; Villanueva A; Sureda A
Dis Model Mech; 2021 Jul; 14(7):. PubMed ID: 33988237
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
19. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
[TBL] [Abstract][Full Text] [Related]
20. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
